Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Dec 1, 2025
Kazia Therapeutics Limited (NASDAQ:KZIA) is an Australian oncology-focused biotechnology company that develops anti-cancer drugs for treating various forms of cancer. Originally incorporated in 1994 as Novogen Limited, the company rebranded to Kazia Therapeutics in November 2017 to better reflect its focus on cancer therapeutics. Based in Sydney, Australia, Kazia went public in 1999 and has been dedicated to advancing novel cancer treatments through clinical development, with particular emphasis on brain-penetrant therapies for difficult-to-treat cancers like glioblastoma.
Latest newsMore news →
Kazia Therapeutics announced that the first patient has been dosed in Arm A of the PNOC035 Phase 2 clinical study evaluating paxalisib in combination with gemcitabine for recurrent or progressive AT/RT brain cancer in patients aged 1 to 39.11d agoKazia Therapeutics expanded its paxalisib clinical trial into HR+/HER2- breast cancer.19d agoKazia Therapeutics announced new clinical data for its lead asset paxalisib in advanced triple-negative breast cancer, reporting a 100% clinical benefit rate in six evaluable patients.24d ago